Compounds > gadolinium dtpa
Page last updated: 2024-09-04

gadolinium dtpa and pimonidazole

gadolinium dtpa has been researched along with pimonidazole in 5 studies

Compound Research Comparison

Studies
(gadolinium dtpa)		Trials
(gadolinium dtpa)		Recent Studies (post-2010)
(gadolinium dtpa)		Studies
(pimonidazole)		Trials
(pimonidazole)		Recent Studies (post-2010) (pimonidazole)
12,6546644,05138222116

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Geus-Oei, LF; Heerschap, A; Kaanders, JH; Krabbe, PF; Lok, J; Oyen, WJ; Punt, CJ; Rijpkema, M; Ruers, T; van der Kogel, AJ; van Laarhoven, HW; Wiering, B1
Cho, H; Koutcher, JA; Li, XF; Ling, CC; Lupu, ME; Russell, J; Yang, KM1
Egeland, TA; Gaustad, JV; Gulliksrud, K; Mathiesen, B; Rofstad, EK1
Ellingsen, C; Galappathi, K; Ovrebø, KM; Rofstad, EK1
Ellingsen, C; Galappathi, K; Hompland, T; Mathiesen, B; Rofstad, EK1

Other Studies

5 other study(ies) available for gadolinium dtpa and pimonidazole

ArticleYear
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET.
    Radiology, 2005, Volume: 237, Issue:1

    Topics: Adult; Aged; Cell Hypoxia; Colorectal Neoplasms; Contrast Media; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals

2005
Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.
    Cancer biology & therapy, 2009, Volume: 8, Issue:20

    Topics: Adenocarcinoma; Animals; Atrasentan; Colonic Neoplasms; Combined Modality Therapy; Etanidazole; Gadolinium DTPA; HT29 Cells; Humans; Hydrocarbons, Fluorinated; Hypoxia; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Nitroimidazoles; Perfusion; Pyrrolidines; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome; Xenograft Model Antitumor Assays

2009
Dynamic contrast-enhanced-MRI of tumor hypoxia.
    Magnetic resonance in medicine, 2012, Volume: 67, Issue:2

    Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Contrast Media; Female; Gadolinium DTPA; Humans; Image Enhancement; Image Processing, Computer-Assisted; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sensitivity and Specificity; Whole Body Imaging

2012
Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts.
    International journal of radiation oncology, biology, physics, 2012, May-01, Volume: 83, Issue:1

    Topics: Animals; Biomarkers, Tumor; Cell Hypoxia; Contrast Media; Female; Gadolinium DTPA; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitroimidazoles; Transplantation, Heterologous; Tumor Microenvironment

2012
DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014, Volume: 110, Issue:2

    Topics: Animals; Cell Hypoxia; Cell Survival; Contrast Media; Female; Gadolinium DTPA; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Nitroimidazoles; Radiation-Sensitizing Agents; Radionuclide Imaging; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays

2014